NRx Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NRXP research report →
Companywww.nrxpharma.com
NRX Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior.
- CEO
- Jonathan C. Javitt
- IPO
- 2017
- Employees
- 2
- HQ
- Wilmington, DE, US
Price Chart
Valuation
- Market Cap
- $51.34M
- P/E
- -3.91
- P/S
- 22.39
- P/B
- -6.95
- EV/EBITDA
- -1.69
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 43.26%
- Op Margin
- -746.62%
- Net Margin
- -1070.26%
- ROE
- 107.73%
- ROIC
- 132.90%
Growth & Income
- Revenue
- $1.23M · 0.00%
- Net Income
- $-28,622,000 · -13.91%
- EPS
- $-1.34 · 43.93%
- Op Income
- $-16,224,000
- FCF YoY
- -32.67%
Performance & Tape
- 52W High
- $3.84
- 52W Low
- $1.62
- 50D MA
- $2.53
- 200D MA
- $2.51
- Beta
- 2.02
- Avg Volume
- 964.11K
Get TickerSpark's AI analysis on NRXP
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 27, 26 | Casper Joseph Michael | other | 100,000 |
| Jan 27, 26 | Casper Joseph Michael | other | 100,000 |
| Apr 9, 25 | Javitt Jonathan C | other | 125,000 |
| Apr 9, 25 | McBride Dennis | other | 25,000 |
| Apr 9, 25 | Hurvitz Chaim | other | 25,000 |
| Apr 9, 25 | Flynn Patrick John | other | 50,000 |
| Aug 18, 25 | B Group, Inc. | other | 0 |
| Feb 7, 25 | ABRAMS MICHAEL S | other | 50,000 |
| Dec 17, 24 | Javitt Jonathan C | buy | 40,000 |
| Nov 18, 24 | ABRAMS MICHAEL S | other | 0 |
Our NRXP Coverage
We haven't published any research on NRXP yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate NRXP Report →